As the frequency of autoimmune diseases and organ transplant occurrences rises, the worldwide photopheresis products market is expected to grow. Increased compensation requirements by governments are projected to boost the worldwide photopheresis product market.
Furthermore, commercial strategies including collaboration among key players in the photopheresis sector lead to a deeper understanding of photopheresis' impact on immune regulation in a variety of acute and critical conditions. In February 2019, Mallinckrodt plc and Transimmune AG, a company that develops new immunotherapies, signed a research partnership agreement for the development of antigen presentation cell activation. Both companies intend to look into future Mallinckodt photopheresis technology. The worldwide photopheresis products market has been segmented into hospitals and specialty clinics based on end-user.
Read more @ https://bit.ly/3o8ytya
0
